What is the most definitive treatment for primary enuresis?

Desmopressin (DDAVP) is considered the most definitive treatment for primary enuresis, which is also known as nocturnal enuresis or bedwetting. This condition is prevalent among children and can cause significant distress for both the child and the family. Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that helps to reduce urine production at night, thereby decreasing the frequency of bedwetting incidents.

When the body produces excess urine during the night, it can overwhelm the bladder capacity, leading to enuresis. Desmopressin addresses this by increasing water reabsorption in the kidneys, resulting in less urine output during the nighttime hours. Clinical studies have shown that desmopressin is effective not only in reducing the frequency of bedwetting but also in promoting dry nights in many patients.

Other treatments, while they may have some efficacy in certain cases, do not provide the same level of definitive resolution for the issue of primary enuresis. For instance, oxybutynin chloride, which is often used for bladder dysfunction, may help with bladder capacity but does not directly address the underlying cause of nocturnal enuresis. Imipramine